Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482761 | 0.91 | NR1H4 (0.41) | NR1H4MCHR1BACE1PTGER1CYP3A4 | |
| SCHEMBL1483423 | 0.88 | NR1H4 (0.42) | NR1H4PTGER1CNR1CYP3A4CYP2D6 | |
| SCHEMBL1482332 | 0.87 | DYRK1A (0.39) | NR1H4MCHR1BACE1CNR1 | |
| SCHEMBL1482644 | 0.86 | NR1H4 (0.43) | NR1H4PTGER1CNR1CYP3A4CYP2D6 | |
| SCHEMBL1483050 | 0.84 | KDM4E (0.43) | NR1H4 | |
| SCHEMBL1482749 | 0.84 | P2RX3 (0.43) | NR1H4PTGER1CNR1KCNH2 | |
| SCHEMBL1482695 | 0.83 | MCHR1 (0.39) | NR1H4MCHR1BACE1CNR1 | |
| SCHEMBL1482376 | 0.83 | DRD2 (0.47) | NR1H4PTGER1CNR1CYP3A4CYP2D6 | |
| SCHEMBL1482647 | 0.82 | NR1H4 (0.48) | NR1H4PTGER1CNR1CYP3A4CYP2D6 | |
| SCHEMBL1482186 | 0.81 | NR1H4 (0.49) | NR1H4PTGER1CNR1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | NR1H4 776/4885MCHR1 2753/4885BACE1 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.